Patient P-01686

Synthetic patientNBL-101 · Day 113 · 65–74 · M · baseline S10Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Favorable

GI state

Improving

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

40%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S10
Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 47 SC-12 recommended — Supportive Compound SC-12
Day 48 Patient accepted — Started SC-12 in the companion
Day 54 GI symptom burden −13% vs expected — Supportive Compound SC-12
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient accepted — Started GI-04 in the companion
Day 60 Tolerance state changed — Unstable → Improving
Day 60 ME-01 recommended — Monitoring Escalation ME-01
Day 61 Patient accepted — Started ME-01 in the companion
Day 64 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 66 GI symptom burden −37% vs expected — GI Support Protocol GI-04
Day 72 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days

Nutritional resilience-7
Inflammatory activity+6
GI instability-5
Treatment adherence+3
Toxicity-3

What helped?

Supportive Compound SC-12Day 47
Result: symptom burden −13%
GI Support Protocol GI-04Day 57
Result: symptom burden −37%
Monitoring Escalation ME-01Day 60
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

60%

probability of meaningful tolerance improvement

284 similar trajectories
84% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

35.4/100

worsening · +2.6 vs previous 14 d

Toxicity

Blood

29.9/100

improving · -2.1 vs previous 14 d

Sleep quality

Wearable

38.2/100

improving · +1.1 vs previous 14 d

Energy level

Daily log

4.8/10

stable · +0.0 vs previous 14 d

Stress level

Daily log

4.9/10

stable · +0.2 vs previous 14 d

Steps

Wearable

4,122

stable · -65 vs previous 14 d

Adherence

Companion

54 %

improving · +7.3 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 46 from the failing basin, 44 from restoration.

Would help

NP-02 Dietary Support Protocol
70% improved among 57 similar · onset 10 d · confidence 57%

Would not help

Keep fat low
GI +6.7 next day on high-intake days · n 20
Keep histamine low
GI +4.9 next day on high-intake days · n 22
Keep simple carbs low
GI +3.7 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.7detractor · 95%
Histamine load
+4.9detractor · 95%
Simple carbohydrates
+3.7detractor · 92%
Spicy / capsaicin
+3.2detractor · 68%
Insoluble fibre
+2.9detractor · 70%
Alcohol
-0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 36/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 42
- WearableHRV 33 ms, trending down
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.9 · butyrate capacity 36/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 5.9 h
Steps: 3,800
Resting HR: 71 bpm

Daily log: GI score 35, nutritional resilience 49, adherence 54.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01377	27%	S11	AD-05	no change	42
P-01483	27%	S14	AD-05	no change	35
P-01541	26%	S09	AD-05	no change	43
P-01679	26%	S12	AD-05	no change	39
P-01350	26%	S19	BR-03	no change	34
P-01371	31%	S06	CR-01	improved	63
P-01430	30%	S05	CR-01	improved	54
P-01696	30%	S20	CR-01	improved	59
P-01442	29%	S13	CR-01	improved	61
P-01708	29%	S07	CR-01	improved	59
P-01388	27%	S17	CR-01	improved	59
P-01835	27%	S17	CR-01	improved	56